Recipient and transplant characteristics according to donor age (n = 6978 bone marrow transplantations)
| Characteristic . | Total . | Age of donor . | |||
|---|---|---|---|---|---|
| 18-30 Years . | 31-45 Years . | >46 Years . | P* . | ||
| Disease | |||||
| CML | 2469 (35) | 662 (34) | 1379 (35) | 428 (38) | .62 |
| Chronic phase | 1665 (24) | 448 (23) | 939 (24) | 278 (25) | |
| Accelerated phase | 666 (10) | 177 (9) | 369 (9) | 120 (11) | |
| Blast phase | 138 (2) | 37 (2) | 71 (2) | 30 (3) | |
| AML | 1373 (20) | 401 (21) | 756 (19) | 216 (19) | |
| 1st remission | 268 (4) | 74 (4) | 157 (4) | 37 (3) | |
| 2nd remission | 345 (5) | 102 (5) | 196 (5) | 47 (4) | |
| 3rd or higher remission and relapse | 760 (11) | 225 (12) | 403 (10) | 132 (12) | |
| ALL | 1359 (19) | 397 (21) | 755 (19) | 207 (18) | |
| 1st remission | 282 (4) | 90 (5) | 152 (4) | 40 (4) | |
| 2nd remission | 494 (7) | 134 (7) | 280 (7) | 80 (7) | |
| 3rd or higher remission and relapse | 583 (8) | 173 (9) | 323 (8) | 87 (8) | |
| MDS | 589 (8) | 148 (8) | 356 (9) | 85 (8) | |
| NHL | 205 (3) | 48 (2) | 122 (3) | 35 (3) | |
| Other malignant disease | 235 (3) | 66 (3) | 131 (3) | 38 (3) | |
| SAA | 286 (4) | 82 (4) | 164 (4) | 40 (4) | |
| Other nonmalignant disease | 462 (7) | 119 (6) | 261 (7) | 82 (7) | |
| Female | 2850 (41) | 817 (42) | 1568 (40) | 465 (41) | .27 |
| CMV seropositive† | 3359 (49) | 905 (47) | 1927 (49) | 527 (47) | .62 |
| Match status | |||||
| HLA-A, -B, DRB1 match | 4290 (61) | 1230 (64) | 2385 (61) | 675 (60) | .20 |
| Potential match | 773 (11) | 182 (9) | 475 (12) | 116 (10) | |
| HLA-A mismatch | 719 (10) | 189 (10) | 401 (10) | 129 (11) | |
| HLA-B mismatch | 513 (7) | 140 (7) | 284 (7) | 89 (8) | |
| HLA-DRB1 mismatch | 683 (10) | 182 (9) | 379 (10) | 122 (11) | |
| Race or ethnic group | |||||
| African American | 301 (4) | 97 (5) | 160 (4) | 44 (4) | .009 |
| Asian/Pacific Islander | 180 (3) | 68 (4) | 85 (2) | 27 (2) | |
| White | 6029 (86) | 1609 (84) | 3427 (87) | 993 (88) | |
| Hispanic | 411 (6) | 133 (7) | 217 (6) | 61 (5) | |
| Native American | 16 (<1) | 5 (<1) | 10 (<1) | 1 (<1) | |
| Other | 41 (1) | 11 (1) | 25 (1) | 5 (<1) | |
| Year of infusion | |||||
| 1987-1992 | 1378 (20) | 283 (15) | 865 (22) | 230 (20) | <.0001 |
| 1993-1995 | 2122 (30) | 582 (30) | 1174 (30) | 366 (32) | |
| 1996-1999 | 3478 (50) | 1058 (55) | 1885 (48) | 535 (47) | |
| GVHD prophylaxis | <.0001 | ||||
| T-cell depletion ± other | 1747 (25) | 531 (28) | 965 (25) | 251 (22) | |
| MTX + CsA | 1871 (27) | 535 (28) | 1046 (27) | 290 (26) | |
| MTX + CsA + prednisone | 1178 (17) | 343 (18) | 644 (16) | 191 (17) | |
| MTX ± other | 1563 (22) | 376 (20) | 890 (23) | 297 (26) | |
| Other | 619 (9) | 138 (7) | 379 (10) | 102 (9) | |
| Median age, y (range) | 28.8 (0-66) | 27.4 (0-66) | 29.3 (0-64) | 28.5 (0-66) | .12 |
| Median time, mo (range), from diagnosis to transplant | 15 (0-395) | 14 (0-258) | 15 (0-395) | 15 (0-242) | .04 |
| Median cell dose, ×108/kg (range)‡ | 2.5 (0.1-10) | 2.4 (0.1-10) | 2.5 (0.1-10) | 2.4 (0.1-9.9) | .54 |
| Characteristic . | Total . | Age of donor . | |||
|---|---|---|---|---|---|
| 18-30 Years . | 31-45 Years . | >46 Years . | P* . | ||
| Disease | |||||
| CML | 2469 (35) | 662 (34) | 1379 (35) | 428 (38) | .62 |
| Chronic phase | 1665 (24) | 448 (23) | 939 (24) | 278 (25) | |
| Accelerated phase | 666 (10) | 177 (9) | 369 (9) | 120 (11) | |
| Blast phase | 138 (2) | 37 (2) | 71 (2) | 30 (3) | |
| AML | 1373 (20) | 401 (21) | 756 (19) | 216 (19) | |
| 1st remission | 268 (4) | 74 (4) | 157 (4) | 37 (3) | |
| 2nd remission | 345 (5) | 102 (5) | 196 (5) | 47 (4) | |
| 3rd or higher remission and relapse | 760 (11) | 225 (12) | 403 (10) | 132 (12) | |
| ALL | 1359 (19) | 397 (21) | 755 (19) | 207 (18) | |
| 1st remission | 282 (4) | 90 (5) | 152 (4) | 40 (4) | |
| 2nd remission | 494 (7) | 134 (7) | 280 (7) | 80 (7) | |
| 3rd or higher remission and relapse | 583 (8) | 173 (9) | 323 (8) | 87 (8) | |
| MDS | 589 (8) | 148 (8) | 356 (9) | 85 (8) | |
| NHL | 205 (3) | 48 (2) | 122 (3) | 35 (3) | |
| Other malignant disease | 235 (3) | 66 (3) | 131 (3) | 38 (3) | |
| SAA | 286 (4) | 82 (4) | 164 (4) | 40 (4) | |
| Other nonmalignant disease | 462 (7) | 119 (6) | 261 (7) | 82 (7) | |
| Female | 2850 (41) | 817 (42) | 1568 (40) | 465 (41) | .27 |
| CMV seropositive† | 3359 (49) | 905 (47) | 1927 (49) | 527 (47) | .62 |
| Match status | |||||
| HLA-A, -B, DRB1 match | 4290 (61) | 1230 (64) | 2385 (61) | 675 (60) | .20 |
| Potential match | 773 (11) | 182 (9) | 475 (12) | 116 (10) | |
| HLA-A mismatch | 719 (10) | 189 (10) | 401 (10) | 129 (11) | |
| HLA-B mismatch | 513 (7) | 140 (7) | 284 (7) | 89 (8) | |
| HLA-DRB1 mismatch | 683 (10) | 182 (9) | 379 (10) | 122 (11) | |
| Race or ethnic group | |||||
| African American | 301 (4) | 97 (5) | 160 (4) | 44 (4) | .009 |
| Asian/Pacific Islander | 180 (3) | 68 (4) | 85 (2) | 27 (2) | |
| White | 6029 (86) | 1609 (84) | 3427 (87) | 993 (88) | |
| Hispanic | 411 (6) | 133 (7) | 217 (6) | 61 (5) | |
| Native American | 16 (<1) | 5 (<1) | 10 (<1) | 1 (<1) | |
| Other | 41 (1) | 11 (1) | 25 (1) | 5 (<1) | |
| Year of infusion | |||||
| 1987-1992 | 1378 (20) | 283 (15) | 865 (22) | 230 (20) | <.0001 |
| 1993-1995 | 2122 (30) | 582 (30) | 1174 (30) | 366 (32) | |
| 1996-1999 | 3478 (50) | 1058 (55) | 1885 (48) | 535 (47) | |
| GVHD prophylaxis | <.0001 | ||||
| T-cell depletion ± other | 1747 (25) | 531 (28) | 965 (25) | 251 (22) | |
| MTX + CsA | 1871 (27) | 535 (28) | 1046 (27) | 290 (26) | |
| MTX + CsA + prednisone | 1178 (17) | 343 (18) | 644 (16) | 191 (17) | |
| MTX ± other | 1563 (22) | 376 (20) | 890 (23) | 297 (26) | |
| Other | 619 (9) | 138 (7) | 379 (10) | 102 (9) | |
| Median age, y (range) | 28.8 (0-66) | 27.4 (0-66) | 29.3 (0-64) | 28.5 (0-66) | .12 |
| Median time, mo (range), from diagnosis to transplant | 15 (0-395) | 14 (0-258) | 15 (0-395) | 15 (0-242) | .04 |
| Median cell dose, ×108/kg (range)‡ | 2.5 (0.1-10) | 2.4 (0.1-10) | 2.5 (0.1-10) | 2.4 (0.1-9.9) | .54 |
CML indicates chronic myelogenous leukemia; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA; severe aplastic anemia; CMV; cytomegalovirus; GVHD, graft-versus-host disease; MTX, methotrexate; and CsA, cyclosporine. Values are numbers (percentages) unless otherwise indicated.
Determined by the Wilcoxon rank sum test for discrete variables and the Spearman rank correlation test for continuous variables.
The recipient's CMV serologic status was not available for 56 cases.
T-cell–replete cases only.